NO316801B1 - Interferoninneholdende vandig sammensetning - Google Patents
Interferoninneholdende vandig sammensetning Download PDFInfo
- Publication number
- NO316801B1 NO316801B1 NO19961322A NO961322A NO316801B1 NO 316801 B1 NO316801 B1 NO 316801B1 NO 19961322 A NO19961322 A NO 19961322A NO 961322 A NO961322 A NO 961322A NO 316801 B1 NO316801 B1 NO 316801B1
- Authority
- NO
- Norway
- Prior art keywords
- interferon
- alpha
- benzyl alcohol
- solutions
- per
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title claims description 21
- 108010050904 Interferons Proteins 0.000 title claims description 21
- 229940079322 interferon Drugs 0.000 title claims description 20
- 239000000203 mixture Substances 0.000 title description 6
- 239000000243 solution Substances 0.000 claims description 37
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 21
- 108010047761 Interferon-alpha Proteins 0.000 claims description 18
- 102000006992 Interferon-alpha Human genes 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 7
- 239000005695 Ammonium acetate Substances 0.000 claims description 7
- 235000019257 ammonium acetate Nutrition 0.000 claims description 7
- 229940043376 ammonium acetate Drugs 0.000 claims description 7
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 7
- 239000003599 detergent Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000644 isotonic solution Substances 0.000 claims description 3
- 239000001540 sodium lactate Substances 0.000 claims description 3
- 229940005581 sodium lactate Drugs 0.000 claims description 3
- 235000011088 sodium lactate Nutrition 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 238000003860 storage Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 239000011123 type I (borosilicate glass) Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95105166 | 1995-04-06 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO961322D0 NO961322D0 (no) | 1996-04-01 |
| NO961322L NO961322L (no) | 1996-10-07 |
| NO316801B1 true NO316801B1 (no) | 2004-05-18 |
Family
ID=8219166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19961322A NO316801B1 (no) | 1995-04-06 | 1996-04-01 | Interferoninneholdende vandig sammensetning |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5762923A (fr) |
| EP (1) | EP0736303B1 (fr) |
| JP (1) | JP2758154B2 (fr) |
| KR (1) | KR100212346B1 (fr) |
| CN (1) | CN1066065C (fr) |
| AR (1) | AR002932A1 (fr) |
| AT (1) | ATE183650T1 (fr) |
| AU (1) | AU685356B2 (fr) |
| BR (1) | BR9601276A (fr) |
| CA (1) | CA2172664C (fr) |
| CO (1) | CO4750807A1 (fr) |
| CY (1) | CY2194B1 (fr) |
| CZ (1) | CZ287626B6 (fr) |
| DE (1) | DE69603894T2 (fr) |
| DK (1) | DK0736303T3 (fr) |
| ES (1) | ES2136910T3 (fr) |
| GR (1) | GR3031775T3 (fr) |
| HK (1) | HK1012232A1 (fr) |
| HU (1) | HU227643B1 (fr) |
| IL (1) | IL117752A (fr) |
| MA (1) | MA23838A1 (fr) |
| MY (1) | MY113594A (fr) |
| NO (1) | NO316801B1 (fr) |
| NZ (1) | NZ286300A (fr) |
| PE (1) | PE38897A1 (fr) |
| PL (1) | PL183873B1 (fr) |
| RU (1) | RU2113845C1 (fr) |
| SA (1) | SA96160728B1 (fr) |
| SG (1) | SG52806A1 (fr) |
| TR (1) | TR199600287A2 (fr) |
| TW (1) | TW426523B (fr) |
| ZA (1) | ZA962553B (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO327844B1 (no) * | 1996-12-24 | 2009-10-05 | Biogen Idec Inc | Pakket sett for administrasjon av interferon beta, flytende sammensetning for slikt sett samt fremgangsmåte for fremstilling derav |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| ID28470A (id) * | 1998-03-26 | 2001-05-24 | Schering Corp | Formulasi-formulasi untuk perlindungan terhadap konjugasi polietilen glikol-interferon alfa |
| US6180096B1 (en) | 1998-03-26 | 2001-01-30 | Schering Corporation | Formulations for protection of peg-interferon alpha conjugates |
| DK1069912T3 (da) * | 1998-04-03 | 2007-11-12 | Novartis Vaccines & Diagnostic | Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel |
| JP5281726B2 (ja) | 1998-05-15 | 2013-09-04 | メルク・シャープ・アンド・ドーム・コーポレーション | 慢性Ｃ型肝炎感染を有する、抗ウイルス処置を受けていない患者における、リバビリンおよびインターフェロンαを含む併用療法 |
| ATE307597T1 (de) * | 1998-06-08 | 2005-11-15 | Hoffmann La Roche | Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c |
| IL140984A0 (en) * | 1998-07-23 | 2002-02-10 | Lilly Co Eli | Fsh and fsh variant formulations, products and methods |
| US20030166525A1 (en) | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
| US6783965B1 (en) * | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| ATE498409T1 (de) | 1998-08-06 | 2011-03-15 | Mountain View Pharmaceuticals | Peg-uricase konjugate und verwendung davon |
| JP2002532556A (ja) * | 1998-12-22 | 2002-10-02 | シェリング・コーポレーション | Ｃ型肝炎ウイルス感染のインターロイキン−１０での処置 |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| ATE419001T1 (de) | 1999-04-08 | 2009-01-15 | Schering Corp | Melanoma therapie |
| US6923966B2 (en) * | 1999-04-08 | 2005-08-02 | Schering Corporation | Melanoma therapy |
| US6362162B1 (en) | 1999-04-08 | 2002-03-26 | Schering Corporation | CML Therapy |
| US6605273B2 (en) | 1999-04-08 | 2003-08-12 | Schering Corporation | Renal cell carcinoma treatment |
| KR100399156B1 (ko) * | 1999-11-19 | 2003-09-26 | 주식회사 엘지생명과학 | α-인터페론의 용액제형 |
| CN1175901C (zh) * | 1999-12-06 | 2004-11-17 | 天津华立达生物工程有限公司 | 一种稳定的干扰素水溶液 |
| CA2405557C (fr) | 2000-04-12 | 2013-09-24 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
| US7208167B2 (en) * | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| DE60139339D1 (de) | 2000-11-07 | 2009-09-03 | Novartis Vaccines & Diagnostic | Stabilisierte interferonzusammensetzungen |
| CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
| US8551469B2 (en) | 2001-02-28 | 2013-10-08 | Superlab Far East Limited | Treatment of tumors and viral diseases with recombinant interferon alpha |
| JP2002265383A (ja) * | 2001-03-14 | 2002-09-18 | Mitsubishi Pharma Corp | インターフェロンα注射用液状製剤 |
| US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| WO2002083165A1 (fr) * | 2001-04-10 | 2002-10-24 | Sumitomo Pharmaceuticals Co., Ltd. | Preparations stables destinees a etre injectees |
| LT4947B (lt) | 2001-09-26 | 2002-08-26 | Biotechnologijos Institutas | Interferono alfa farmacinė kompozicija |
| EP2261250B1 (fr) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | Protéines de fusion d'albumine et GCSF |
| KR20050012224A (ko) | 2002-05-21 | 2005-01-31 | 다이이찌 산토리 파마 가부시키가이샤 | 그렐린 함유 의약 조성물 |
| CA2518903C (fr) | 2003-04-02 | 2013-02-05 | Ares Trading S.A. | Formulations pharmaceutiques fsh et lh |
| TWI272948B (en) * | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
| AR044302A1 (es) * | 2003-05-13 | 2005-09-07 | Ares Trading Sa | Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos |
| ES2414705T3 (es) | 2003-06-20 | 2013-07-22 | Ares Trading S.A. | Formulaciones liofilizadas de FSH/LH |
| DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| AR045258A1 (es) * | 2003-08-21 | 2005-10-19 | Altana Pharma Ag | Un producto farmaceutico para inyeccion |
| US7585647B2 (en) | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
| JP4896745B2 (ja) | 2004-02-02 | 2012-03-14 | アンブレツクス・インコーポレイテツド | 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用 |
| EA012205B1 (ru) | 2004-05-17 | 2009-08-28 | Арес Трейдинг С.А. | Гидрогелевые препараты интерферона |
| WO2005117948A1 (fr) | 2004-06-01 | 2005-12-15 | Ares Trading S.A. | Procede de stabilisation de proteines |
| CN1993139B (zh) * | 2004-06-01 | 2011-02-16 | 阿雷斯贸易股份有限公司 | 稳定的干扰素液体制剂 |
| US7632491B2 (en) | 2004-08-12 | 2009-12-15 | Schering Corporation | Stable pegylated interferon formulation |
| JP4951344B2 (ja) * | 2004-08-24 | 2012-06-13 | 第一三共株式会社 | 生理活性ペプチド液状製剤 |
| WO2006110819A2 (fr) | 2005-04-11 | 2006-10-19 | Savient Pharmaceuticals, Inc. | Formes variantes de l'urate oxydase et leur utilisation |
| ES2302402B1 (es) | 2005-06-16 | 2009-05-08 | Proyecto De Biomedicina Cima, S.L. | Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. |
| CA2618068C (fr) | 2005-08-05 | 2016-02-16 | Amgen Inc. | Formulations pharmaceutiques de proteine aqueuse stable ou d'anticorps et leur preparation |
| CU23432B6 (es) | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras |
| WO2008026044A2 (fr) * | 2006-08-31 | 2008-03-06 | Wockhardt Research Centre | Compositions pharmaceutiques de bupropion |
| CN104524567A (zh) | 2007-01-16 | 2015-04-22 | 阿布维公司 | 用于治疗银屑病的方法 |
| WO2008145323A1 (fr) * | 2007-05-31 | 2008-12-04 | F. Hoffmann-La Roche Ag | Formulation pharmaceutique comprenant des interférons |
| CN101636411B (zh) * | 2007-09-04 | 2013-01-09 | 厦门伯赛基因转录技术有限公司 | 聚乙二醇修饰的干扰素α2a及其制备方法和应用 |
| ES2382124T3 (es) * | 2007-09-04 | 2012-06-05 | Biosteed Gene Expression Tech. Co., Ltd. | Interferón alfa 2b modificado con polietilenglicol y método de preparación y aplicaciones de este |
| US8216571B2 (en) * | 2007-10-22 | 2012-07-10 | Schering Corporation | Fully human anti-VEGF antibodies and methods of using |
| PT2234645E (pt) | 2007-12-20 | 2012-05-21 | Merck Serono Sa | Formulações de peg-interferão-beta |
| US20110293557A1 (en) | 2008-06-13 | 2011-12-01 | Proyecto De Biomedicina Cima, S.L. | Conjugates for the administration of biologically active compounds |
| JP2012502906A (ja) * | 2008-09-17 | 2012-02-02 | ネクター セラピューティックス | オリゴマー−プロテアーゼ阻害剤コンジュゲート |
| BRPI1010069A2 (pt) | 2009-06-25 | 2016-03-15 | Savient Pharmaceuticals Inc | "método para prevenir reações à infusão durante terapia por uricase peguilada em pacientes; e método para diagnosticar se um paciente tratado com uricase peguilada desenvolverá reações à infusão ou desenvolverá liberação de uricase peguilada mediada por anticorpo sem a medição de títulos de anticorpos anti-peg e anti-uricase peguilada" |
| CN102101886A (zh) | 2009-12-18 | 2011-06-22 | 四川辉阳生命工程股份有限公司 | 构象改变的重组干扰素晶体、其三维结构及应用 |
| RU2447083C1 (ru) * | 2010-07-20 | 2012-04-10 | Закрытое Акционерное Общество "Биокад" | НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ |
| KR101303388B1 (ko) * | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
| CN102526758B (zh) * | 2012-02-23 | 2013-02-13 | 北京三元基因工程有限公司 | 一种聚乙二醇化干扰素稳定的水溶液 |
| TWI718086B (zh) | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| JP6445169B2 (ja) * | 2014-09-23 | 2018-12-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | α型インターフェロンを含有する安定したベンジルアルコールフリーの水溶液製剤 |
| RU2768656C1 (ru) * | 2021-09-10 | 2022-03-24 | Илья Александрович Марков | Противовирусное средство в жидкой форме и способ его приготовления |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61277633A (ja) * | 1985-05-31 | 1986-12-08 | Toray Ind Inc | インタ−フエロン組成物 |
| EP0284249A1 (fr) * | 1987-03-13 | 1988-09-28 | Interferon Sciences, Inc. | Composition lyophilisée de lymphokine |
| IL88233A (en) * | 1987-11-03 | 1993-08-18 | Genentech Inc | Gamma interferon formulation |
| JPH0651642B2 (ja) * | 1988-11-14 | 1994-07-06 | 大塚製薬株式会社 | インターフェロン経鼻投与用製剤 |
| WO1990005535A1 (fr) * | 1988-11-14 | 1990-05-31 | Otsuka Pharmaceutical Co., Ltd. | Preparation a base d'interferon pour administration nasale |
| CA2033714A1 (fr) * | 1990-01-25 | 1991-07-26 | Alberto Ferro | Preparations pharmaceutiques |
| DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| IL109350A (en) * | 1993-05-12 | 2001-01-28 | Genentech Inc | Stable liquid preparations of gamma interferon |
-
1996
- 1996-03-22 JP JP8066118A patent/JP2758154B2/ja not_active Expired - Lifetime
- 1996-03-22 TW TW085103497A patent/TW426523B/zh not_active IP Right Cessation
- 1996-03-26 CA CA002172664A patent/CA2172664C/fr not_active Expired - Lifetime
- 1996-03-29 ZA ZA962553A patent/ZA962553B/xx unknown
- 1996-03-30 AT AT96105142T patent/ATE183650T1/de active
- 1996-03-30 DK DK96105142T patent/DK0736303T3/da active
- 1996-03-30 ES ES96105142T patent/ES2136910T3/es not_active Expired - Lifetime
- 1996-03-30 EP EP96105142A patent/EP0736303B1/fr not_active Expired - Lifetime
- 1996-03-30 DE DE69603894T patent/DE69603894T2/de not_active Expired - Lifetime
- 1996-04-01 NZ NZ286300A patent/NZ286300A/en not_active IP Right Cessation
- 1996-04-01 AU AU50446/96A patent/AU685356B2/en not_active Expired
- 1996-04-01 IL IL11775296A patent/IL117752A/xx not_active IP Right Cessation
- 1996-04-01 PE PE1996000231A patent/PE38897A1/es not_active IP Right Cessation
- 1996-04-01 NO NO19961322A patent/NO316801B1/no not_active IP Right Cessation
- 1996-04-01 MA MA24195A patent/MA23838A1/fr unknown
- 1996-04-02 CO CO96016207A patent/CO4750807A1/es unknown
- 1996-04-03 SG SG1996010030A patent/SG52806A1/en unknown
- 1996-04-03 AR ARP960102079A patent/AR002932A1/es unknown
- 1996-04-03 HU HU9600857A patent/HU227643B1/hu unknown
- 1996-04-04 US US08/627,563 patent/US5762923A/en not_active Expired - Lifetime
- 1996-04-04 BR BR9601276A patent/BR9601276A/pt not_active IP Right Cessation
- 1996-04-04 TR TR96/00287A patent/TR199600287A2/xx unknown
- 1996-04-04 CN CN96100545A patent/CN1066065C/zh not_active Expired - Lifetime
- 1996-04-04 KR KR1019960010123A patent/KR100212346B1/ko not_active IP Right Cessation
- 1996-04-04 MY MYPI96001275A patent/MY113594A/en unknown
- 1996-04-04 CZ CZ1996994A patent/CZ287626B6/cs not_active IP Right Cessation
- 1996-04-05 PL PL96313655A patent/PL183873B1/pl unknown
- 1996-04-05 RU RU96107889A patent/RU2113845C1/ru active
- 1996-04-08 SA SA96160728A patent/SA96160728B1/ar unknown
-
1998
- 1998-12-15 HK HK98113442A patent/HK1012232A1/xx not_active IP Right Cessation
-
1999
- 1999-11-05 GR GR990402866T patent/GR3031775T3/el unknown
-
2000
- 2000-09-07 CY CY0000045A patent/CY2194B1/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO327844B1 (no) * | 1996-12-24 | 2009-10-05 | Biogen Idec Inc | Pakket sett for administrasjon av interferon beta, flytende sammensetning for slikt sett samt fremgangsmåte for fremstilling derav |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2172664C (fr) | Solution d'interferon | |
| US5981485A (en) | Human growth hormone aqueous formulation | |
| CA2337745C (fr) | Formule aqueuse d'hormone de croissance humaine | |
| US5763394A (en) | Human growth hormone aqueous formulation | |
| NO320604B1 (no) | Stabile, vandige alfa-interferonopplosningsformuleringer | |
| CZ298597B6 (cs) | Zpusob postupné vazby polyethylenglykolových skupin na polypeptid | |
| CA2532475A1 (fr) | Formulation destinee a un agent pharmaceutique proteique ne contenant pas d'albumine serique humaine ajoutee (hsa) | |
| JP2001506609A (ja) | 生理活性の増加した多量体エリスロポエチン | |
| TW201223541A (en) | Liquid formulations of long acting interferon alpha conjugate | |
| AU754002B2 (en) | Formulations for protection of peg-interferon alpha conjugates | |
| CN112915201A (zh) | 包含抗il-17抗体的液体制剂 | |
| WO2016046101A1 (fr) | Formulations stables, exemptes d'alcool benzylique, d'une solution aqueuse contenant de l'interféron de type alpha | |
| KR100534622B1 (ko) | 에리트로포이에틴과 인간 혈청알부민의 포합체 | |
| Pasut | PEGylated Protein Drugs: Basic Science and Clinical Applications 205 Edited by FM Veronese© 2009 Birkhäuser Verlag/Switzerland | |
| AU4605401A (en) | Multimeric erythropoietin with increased biological activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |